NEW YORK (GenomeWeb News) - PerkinElmer said today it has completed its successful tender offer to acquire ViaCell by buying more than 90 percent of the company's outstanding common stock.
PerkinElmer said it purchased approximately 37.9 million ViaCell shares through the tender offer, which expired Thursday night. PerkinElmer paid $7.25 a share for a total of more than $274 million.  

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.